PMID- 31465912
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20200213
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 75
DP  - 2019 Oct
TI  - Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and 
      meta-analysis.
PG  - 105841
LID - S1567-5769(19)31244-5 [pii]
LID - 10.1016/j.intimp.2019.105841 [doi]
AB  - OBJECTIVES: Interleukin(IL)-23 is a key cytokine in the pathogenesis of 
      psoriasis, this meta-analysis was to analyze the efficacy and safety of IL-23p19 
      blockers in patients with plaque psoriasis. METHODS: A systematic review of the 
      literature was performed to collect double-blind randomized controlled 
      trials(RCTs). The pooled relative risk(RR) with 95% confidence interval(CI) was 
      calculated. All analyses were conducted with intention-to-treat basis. RESULTS: A 
      total of 13 studies contained 5155 plaque psoriasis patients were included in our 
      meta-analysis. The results indicated that IL-23p19 blockers had better efficacy 
      than placebo for Psoriasis Area Severity Index score reductions from baseline of 
      75% or more (PASI75) (RR = 11.47, P < 0.001) and static Physician's Global 
      Assessment score of 0 or 1(sPGA0/1) (RR = 11.32, P < 0.001). IL-23p19 blockers 
      have similar safety with placebo about the incidence of adverse events(AEs) 
      (RR = 1.22, P = 0.096) and serious adverse events(SAEs) (RR = 2.93, P = 0.965), 
      but IL-23p19 blockers carried an increased incidence rate of infections 
      (RR = 1.39, P < 0.001). While compared with adalimumab and ustekinumab, IL-23p19 
      blockers were more effective and had the similar tolerance. Among three IL-23p19 
      blockers, guselkumab was the most efficacious treatments, and risankizumab was 
      better tolerated than the others. CONCLUSION: The IL-23p19 blockers have 
      excellent efficacy and great safety in plaque psoriasis patients, but long-term 
      safety remains to be determined.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Xu, Shanshan
AU  - Xu S
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, 81 Meishan Road, Hefei, Anhui 230032, China; The Key 
      Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan 
      Road, Hefei, Anhui 230032, China.
FAU - Zhang, Xiaoyi
AU  - Zhang X
AD  - Department of Health Toxicology, School of Public Health, Anhui Medical 
      University, 81 Meishan Road, Hefei, Anhui 230032, China.
FAU - Pan, Meijuan
AU  - Pan M
AD  - Department of Rheumatism and Immunity, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, Anhui 230022, China.
FAU - Shuai, Zongwen
AU  - Shuai Z
AD  - Department of Rheumatism and Immunity, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, Anhui 230022, China.
FAU - Xu, Shengqian
AU  - Xu S
AD  - Department of Rheumatism and Immunity, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, Anhui 230022, China.
FAU - Pan, Faming
AU  - Pan F
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui 
      Medical University, 81 Meishan Road, Hefei, Anhui 230032, China; The Key 
      Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan 
      Road, Hefei, Anhui 230032, China. Electronic address: famingpan@ahmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190826
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Interleukin-23 Subunit p19)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Humans
MH  - Interleukin-23 Subunit p19/*antagonists & inhibitors
MH  - Psoriasis/*drug therapy
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Guselkumab
OT  - IL-23p19
OT  - Meta-analysis
OT  - Psoriasis
OT  - Risankizumab
OT  - Tildrakizumab
EDAT- 2019/08/30 06:00
MHDA- 2020/02/14 06:00
CRDT- 2019/08/30 06:00
PHST- 2019/07/02 00:00 [received]
PHST- 2019/08/18 00:00 [revised]
PHST- 2019/08/19 00:00 [accepted]
PHST- 2019/08/30 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
PHST- 2019/08/30 06:00 [entrez]
AID - S1567-5769(19)31244-5 [pii]
AID - 10.1016/j.intimp.2019.105841 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Oct;75:105841. doi: 10.1016/j.intimp.2019.105841. Epub 
      2019 Aug 26.